When stomach cancer spreads beyond its original site to other parts of the body, it becomes metastatic gastric cancer—a challenging condition that requires thoughtful, personalized care. While treatment may not cure the disease at this stage, it can help control symptoms, slow cancer growth, and improve quality of life for a meaningful period.

Understanding Treatment Goals in Advanced Disease

Metastatic gastric cancer, also called stage 4 or advanced stomach cancer, means that cancer cells that started in the stomach have traveled to other organs or tissues in the body. The most common places where stomach cancer spreads include the liver, the lining of the abdominal cavity (called the peritoneum), the lungs, and bones. When cancer has reached this stage, the approach to treatment shifts from attempting a cure to focusing on managing symptoms and extending life as comfortably as possible.^[2][3]

The treatment journey for someone with metastatic gastric cancer depends on several factors. These include where the cancer has spread, what treatments have already been tried, the person’s overall health and strength, and their personal preferences about care. Medical teams consider the stage of disease, whether specific proteins like HER2 (human epidermal growth factor receptor 2) are present on cancer cells, and whether the cancer has certain genetic or molecular features that might respond to targeted treatments.^[5][10]

For most people diagnosed at this stage, the main goal is to prolong survival while maintaining quality of life. This involves controlling cancer growth, reducing pain and discomfort, and helping patients maintain their ability to eat and stay active. Treatment decisions are made collaboratively between patients, their families, and a team of specialists including medical oncologists, surgeons, dietitians, and palliative care providers.^[9]

It is important to understand that metastatic gastric cancer cannot usually be cured. However, various treatment options approved by medical societies and health authorities exist, and researchers continue to investigate new therapies through clinical trials. The median survival for people with metastatic gastric cancer receiving standard chemotherapy is approximately 7 to 14 months, though individual outcomes vary widely based on treatment response and other factors.^[6][14]

Standard Treatment Approaches

The cornerstone of treatment for metastatic gastric cancer is systemic chemotherapy, which uses drugs that travel throughout the body to attack cancer cells wherever they may be. Chemotherapy can help shrink tumors, slow disease progression, and relieve symptoms such as pain, nausea, and difficulty swallowing. Without treatment, the median survival for advanced gastric adenocarcinoma is only about 3 to 5 months, but chemotherapy can extend this to 6 to 14 months in clinical trials.^[6][9]

The most commonly used chemotherapy drugs for metastatic gastric cancer include fluoropyrimidines (such as 5-fluorouracil or capecitabine), which interfere with cancer cell growth, and platinum compounds (such as cisplatin or oxaliplatin), which damage the DNA inside cancer cells. These drugs are often given together as a combination regimen, which tends to be more effective than using a single drug. Other chemotherapy agents that may be used include docetaxel, paclitaxel, and epirubicin, depending on the patient’s condition and previous treatments.^[9][13]

For patients whose tumors test positive for the HER2 protein (approximately 10 to 20 percent of gastric cancers), trastuzumab (Herceptin) is added to chemotherapy. Trastuzumab is a type of targeted therapy that attaches to the HER2 protein on cancer cells and helps stop them from growing. The landmark ToGA trial showed that adding trastuzumab to chemotherapy significantly improved survival in patients with HER2-positive metastatic gastric cancer, making it a new standard of care. Because of this, testing all patients with metastatic gastric or gastroesophageal junction cancer for HER2 status has become an important part of diagnosis.^[8][9]

Another targeted drug approved for metastatic gastric cancer is ramucirumab (Cyramza), which works by blocking the formation of new blood vessels that tumors need to grow—a process called angiogenesis. Ramucirumab can be used alone or combined with paclitaxel chemotherapy for patients whose cancer has progressed after initial treatment. Clinical trials have shown that this combination can extend survival compared to chemotherapy alone.^[15]

Newer additions to the treatment landscape include immune checkpoint inhibitors, which are a form of immunotherapy. These drugs, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), help the body’s immune system recognize and attack cancer cells. They may be used in combination with chemotherapy for advanced or metastatic stomach cancer. Another targeted therapy, trastuzumab deruxtecan (Enhertu), is available for HER2-positive stomach cancer that has progressed after trastuzumab treatment. This drug combines trastuzumab with a chemotherapy agent to deliver treatment directly to cancer cells.^[15]

The duration of chemotherapy treatment varies depending on how well the cancer responds and how well the patient tolerates the medications. Typically, chemotherapy is given in cycles—periods of treatment followed by rest periods to allow the body to recover. Treatment continues as long as it is controlling the cancer and not causing unacceptable side effects. When first-line chemotherapy stops working, patients may be offered second-line treatment with different drugs.^[9]

Common side effects of chemotherapy for gastric cancer include nausea and vomiting, loss of appetite, fatigue, diarrhea or constipation, mouth sores, hair loss, and increased risk of infection due to low blood cell counts. Platinum-based drugs can cause nerve damage (called neuropathy) that leads to tingling or numbness in the hands and feet. Targeted therapies have their own side effects: trastuzumab can affect heart function, while ramucirumab may cause high blood pressure or bleeding. Immunotherapy drugs can trigger immune-related side effects affecting various organs. Healthcare teams provide supportive medications and guidance to manage these effects and maintain quality of life during treatment.^[8][9]

In some carefully selected patients with metastatic disease, surgery may still play a role—not to cure the cancer, but to relieve symptoms. Palliative surgery can help address complications such as severe bleeding, blockage of the stomach opening, or pain. For example, if a tumor is blocking food from passing through, surgeons might place a hollow tube called a stent to keep the passage open, or they might remove part of the stomach. Studies have shown that in some cases, combining surgery with chemotherapy may offer better survival outcomes than chemotherapy alone, with median survival reaching 14.2 months compared to 7 months for chemotherapy alone. However, this approach is only suitable for patients who are healthy enough to undergo surgery.^[6][14][15]

Radiation therapy is another treatment option that can help relieve specific symptoms of advanced gastric cancer. External radiation therapy uses high-energy beams to target cancer tissue. It may be used alone or combined with chemotherapy (called chemoradiation) to reduce pain, stop bleeding, ease difficulty swallowing, or treat a blockage caused by the tumor. Radiation is typically aimed at specific areas where the cancer is causing problems rather than being used as a systemic treatment.^[15][17]

Innovative Therapies in Clinical Trials

Clinical trials are research studies that test new treatments or new ways of using existing treatments. For patients with metastatic gastric cancer, participating in a clinical trial may provide access to promising therapies that are not yet widely available. Researchers around the world are actively investigating novel drugs and treatment combinations that target different aspects of cancer biology.^[8]

One major area of investigation involves more advanced immunotherapy approaches. While drugs like pembrolizumab and nivolumab are already approved, researchers are testing them in different combinations and sequences, as well as exploring newer immune checkpoint inhibitors. These trials are examining which patients are most likely to benefit based on biomarkers such as PD-L1 (programmed death-ligand 1) expression and microsatellite instability (MSI). Patients whose tumors show high levels of PD-L1 or are MSI-high tend to respond better to immunotherapy. Studies have shown particularly impressive results in patients with MSI-high or mismatch repair deficient (dMMR) metastatic gastric cancer treated with anti-PD-1 antibodies.^[8][15]

Another exciting development in clinical trials involves novel anti-HER2 therapies beyond trastuzumab. Trastuzumab deruxtecan (T-DXd), which is now approved after previous HER2-targeted treatment, continues to be studied in earlier lines of therapy. This drug is an antibody-drug conjugate—it combines an antibody that targets HER2 with a powerful chemotherapy agent attached to it, allowing more precise delivery of treatment to cancer cells while sparing healthy tissue. Another antibody-drug conjugate being tested is disitamab vedotin (RC48), which has shown promising results in trials. These agents represent substantial breakthroughs in the treatment of HER2-positive gastric cancer.^[8]

Researchers are also investigating drugs that target different molecular pathways involved in cancer growth. Some clinical trials focus on inhibitors of VEGF (vascular endothelial growth factor), which is involved in the formation of blood vessels that feed tumors. Beyond ramucirumab, other anti-angiogenic agents are being tested. Additional targets being explored include mTOR (mammalian target of rapamycin), a protein that helps regulate cell growth, and EGFR (epidermal growth factor receptor 1), which is overexpressed in some gastric cancers.^[8][9]

Clinical trials are typically divided into phases. Phase I trials primarily test the safety of a new treatment and determine the appropriate dose to use. They involve small numbers of patients and focus on identifying side effects. Phase II trials evaluate whether the treatment shows promise in fighting the cancer—whether tumors shrink or stop growing. These studies involve more patients and begin to assess effectiveness. Phase III trials compare the new treatment to the current standard of care in large groups of patients to determine if the new approach offers better outcomes. Positive Phase III trial results are typically required before a drug can be approved for widespread use.^[8]

One area of active research involves identifying biomarkers that can predict which patients will respond to specific treatments. This includes not only HER2 and PD-L1 testing, but also looking at the genetic makeup of tumors through comprehensive molecular profiling. Techniques such as next-generation sequencing allow doctors to identify multiple genetic changes in a tumor at once, potentially revealing targets for existing or experimental drugs. This personalized medicine approach aims to match each patient with the treatment most likely to benefit them based on their tumor’s unique characteristics.^[8]

Clinical trials for gastric cancer are conducted in many locations around the world, including specialized cancer centers in the United States, Europe, and Asia (particularly in countries with high rates of gastric cancer such as Japan, Korea, and China). Patient eligibility for trials depends on several factors including the stage and type of cancer, previous treatments received, overall health status, and specific biomarkers present in the tumor. Patients interested in clinical trials should discuss options with their oncology team.^[8]

Some early results from clinical trials have been encouraging. For instance, studies of combination immunotherapy regimens have shown improvements in clinical parameters such as response rates (the percentage of patients whose tumors shrink) and progression-free survival (how long patients live before their cancer worsens). Trials of newer targeted therapies have demonstrated positive safety profiles with manageable side effects alongside evidence of clinical benefit. While these results are preliminary and the treatments are still being evaluated, they represent hope for future improvements in gastric cancer care.^[8]

Most Common Treatment Methods

• Chemotherapy
  • Fluoropyrimidines (5-fluorouracil, capecitabine) combined with platinum compounds (cisplatin, oxaliplatin) form the backbone of first-line treatment
  • Other agents include docetaxel, paclitaxel, and epirubicin
  • Two-drug cytotoxic regimens are preferred for advanced disease due to lower toxicity
  • Median survival with chemotherapy alone ranges from 6 to 14 months in clinical trials
• Targeted Therapy
  • Trastuzumab (Herceptin) added to chemotherapy for HER2-positive gastric cancer
  • Trastuzumab deruxtecan (Enhertu) for HER2-positive disease after trastuzumab treatment
  • Ramucirumab (Cyramza) alone or with paclitaxel when initial chemotherapy stops working
  • Zolbetuximab (Vyloy) with chemotherapy for HER2-negative stomach cancer
• Immunotherapy
  • Nivolumab (Opdivo) combined with chemotherapy for advanced or metastatic stomach cancer
  • Pembrolizumab (Keytruda) used with chemotherapy and trastuzumab in advanced cases
  • Particularly effective in MSI-high or mismatch repair deficient tumors
• Palliative Surgery
  • Subtotal or total gastrectomy to remove tumor causing symptoms
  • Stent placement to relieve blockages at the stomach opening
  • Feeding tube insertion when oral nutrition becomes impossible
  • Surgery to address bowel obstruction or bypass blocked intestinal segments
  • Selected patients receiving surgery plus chemotherapy may have median survival of 14.2 months
• Radiation Therapy
  • External radiation alone or combined with chemotherapy
  • Used to relieve symptoms including bleeding, pain, difficulty swallowing, and blockages
  • Targets specific problem areas rather than treating cancer systemically

Managing Symptoms and Supporting Quality of Life

Living with metastatic gastric cancer involves more than just receiving cancer treatments. Symptom management and supportive care are crucial components of the overall treatment plan. Many symptoms can be effectively controlled with appropriate interventions, allowing patients to maintain a better quality of life.

Fatigue is one of the most common symptoms experienced by people with advanced cancer. This overwhelming tiredness can result from the cancer itself, from treatments like chemotherapy, or from anemia (low red blood cell counts). Healthcare teams can help by prescribing medications, recommending blood transfusions if anemia is severe, and suggesting ways to conserve energy. Balancing rest with gentle exercise—such as short walks—can actually help reduce fatigue rather than worsen it. Breaking the day into manageable segments with planned rest periods allows patients to accomplish activities that matter to them.^[17]

Loss of appetite and unintended weight loss are particularly challenging issues in gastric cancer. The tumor’s location in the stomach can directly interfere with eating, and treatments may cause nausea or change how food tastes. Eating several small meals throughout the day may be easier than attempting three large ones. High-calorie nutritional drinks can help boost calorie intake when eating solid food becomes difficult. Working with a registered dietitian who specializes in oncology can provide personalized strategies tailored to individual needs and preferences.^[17][19][21]

Nausea and vomiting can result from the cancer itself, from chemotherapy, from pain medications, or from constipation. Modern anti-nausea medications (called antiemetics) are quite effective when used appropriately. Some patients find natural remedies like ginger—whether as fresh ginger tea, crystallized ginger candy, or ginger drinks—helpful for mild nausea. It is important to communicate with the healthcare team about nausea so that medications can be adjusted as needed.^[17]

Pain management is a critical aspect of care for many patients with metastatic gastric cancer. Pain may come from the tumor itself, from cancer that has spread to bones or other organs, or from treatments. A wide variety of pain medications exist, ranging from over-the-counter options to stronger prescription drugs including opioids. When used appropriately under medical supervision, pain can usually be controlled well. The goal is to keep patients as pain-free as possible so they can maintain activities and quality of life.^[17]

Blockages in the stomach or intestines can cause severe pain, vomiting, and inability to eat. These are medical emergencies that require hospital care. Treatment options include placing stents to keep passages open, using laser therapy to burn away tumor tissue causing the blockage, or performing surgery to bypass or remove the obstructed area. These interventions can provide significant relief and allow patients to resume eating and drinking.^[15][17]

The emotional and psychological impact of living with metastatic cancer should not be underestimated. Feelings of anxiety, uncertainty, sadness, and fear are completely normal responses to this diagnosis. Many cancer centers offer counseling services, support groups, and resources to help patients and their families cope. Connecting with others who are going through similar experiences can provide valuable emotional support and practical advice.^[2]

Advance care planning—discussing preferences for future medical care including what treatments a person would or would not want if their condition worsens—is an important conversation to have with loved ones and healthcare providers. While difficult, these discussions can provide peace of mind and ensure that care aligns with personal values and wishes.^[21]